IL17A and rheumatoid arthritis: Indeed, studies of PC–BSA were the starting point for our development of drug‐like derivatives that mimic the ability of ES‐62 to suppress CIA by targeting pathogenic IL‐17 responses (47) and provide proof‐of‐concept that exploiting the actions of helminth‐derived immunomodulators may potentially open novel avenues for drug discovery in RA.